BACKGROUND: Pump thrombosis is the most severe and acute complication of left ventricular assist device (LVAD) therapy and treatment remains challenging. Whilst lysis therapy is often not successful, the exchange of the occluded LVAD is currently the most applied therapeutic treatment for this event. With this study we examine the effects of minimal-invasive LVAD exchange on the rate re-thrombosis and outcomes as well as adverse events in the study group. METHODS: Between February 2004 and December 2015 more than 600 LVADs were implanted at our institution. We retrospectively studied a patient cohort of 41 patients who underwent LVAD exchange because of pump thrombosis at a single institution. Outcomes, rates of re-thrombosis and adverse events were analyzed. RESULTS: Between February 2004 and December 2015, 87 exchanges of LVADs were performed at a single center. In 41 cases pump thrombosis was the reason for LVAD exchange. A total of 28 patient years (10,276 days) were analyzed. Average ICU stay was 15.8±20.4 days and average in-hospital stay 38.1±37.3 days after LVAD exchange. After thirty days the survival rate was 80.5%, 75.6% after 6 months and 70.7% one year after LVAD exchange. Out of the study cohort, three patients have successfully undergone heart transplantation. Twelve patients suffered a stroke postoperatively (29%). Twelve patients needed postoperative dialysis (29%). No technical complications of the VAD were recorded in the study group. Two patients underwent successful LVAD explantation due to myocardial recovery. One year after LVAD exchange, 14 patients underwent re-exchange due to pump thrombosis (34%). Eight patients suffered from a LVAD related infection out of which two patients were treated by pump exchange. A total of 12 patients died during the complete one year follow up of this study (29%). Four patients died in the second, two in the third and one in the fourth year after LVAD exchange. The remaining 17 patients are still ongoing on the device.Conclusions: It is generally feasible to treat pump thrombosis via LVAD exchange. Yet, the exchange procedure is not without risk and the risk of re-thrombosis (34%), stroke (29%), postoperative dialysis (29%) and perioperative complications remains high.
BACKGROUND: Pump thrombosis is the most severe and acute complication of left ventricular assist device (LVAD) therapy and treatment remains challenging. Whilst lysis therapy is often not successful, the exchange of the occluded LVAD is currently the most applied therapeutic treatment for this event. With this study we examine the effects of minimal-invasive LVAD exchange on the rate re-thrombosis and outcomes as well as adverse events in the study group. METHODS: Between February 2004 and December 2015 more than 600 LVADs were implanted at our institution. We retrospectively studied a patient cohort of 41 patients who underwent LVAD exchange because of pump thrombosis at a single institution. Outcomes, rates of re-thrombosis and adverse events were analyzed. RESULTS: Between February 2004 and December 2015, 87 exchanges of LVADs were performed at a single center. In 41 cases pump thrombosis was the reason for LVAD exchange. A total of 28 patient years (10,276 days) were analyzed. Average ICU stay was 15.8±20.4 days and average in-hospital stay 38.1±37.3 days after LVAD exchange. After thirty days the survival rate was 80.5%, 75.6% after 6 months and 70.7% one year after LVAD exchange. Out of the study cohort, three patients have successfully undergone heart transplantation. Twelve patients suffered a stroke postoperatively (29%). Twelve patients needed postoperative dialysis (29%). No technical complications of the VAD were recorded in the study group. Two patients underwent successful LVAD explantation due to myocardial recovery. One year after LVAD exchange, 14 patients underwent re-exchange due to pump thrombosis (34%). Eight patients suffered from a LVAD related infection out of which two patients were treated by pump exchange. A total of 12 patients died during the complete one year follow up of this study (29%). Four patients died in the second, two in the third and one in the fourth year after LVAD exchange. The remaining 17 patients are still ongoing on the device.Conclusions: It is generally feasible to treat pump thrombosis via LVAD exchange. Yet, the exchange procedure is not without risk and the risk of re-thrombosis (34%), stroke (29%), postoperative dialysis (29%) and perioperative complications remains high.
Authors: Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2011-10 Impact factor: 10.247
Authors: Jan D Schmitto; Jasmin S Hanke; Sebastian V Rojas; Murat Avsar; Axel Haverich Journal: J Heart Lung Transplant Date: 2015-03-07 Impact factor: 10.247
Authors: Ivan Netuka; Pierre-Yves Litzler; Michael Berchtold-Herz; Erwan Flecher; Daniel Zimpfer; Laura Damme; Kartik S Sundareswaran; David J Farrar; Jan D Schmitto Journal: Ann Thorac Surg Date: 2016-10-13 Impact factor: 4.330
Authors: James K Kirklin; David C Naftel; Francis D Pagani; Robert L Kormos; Susan Myers; Michael A Acker; Joseph Rogers; Mark S Slaughter; Lynne W Stevenson Journal: J Heart Lung Transplant Date: 2015-12 Impact factor: 10.247
Authors: Jasmin S Hanke; Sebastian V Rojas; Günes Dogan; Christina Feldmann; Erik Beckmann; Ezin Deniz; Bettina Wiegmann; Jana-Elena Michaelis; L Christian Napp; Dominik Berliner; Malakh Shrestha; Johann Bauersachs; Axel Haverich; Jan D Schmitto Journal: Eur J Cardiothorac Surg Date: 2017-05-01 Impact factor: 4.191
Authors: Randall C Starling; Nader Moazami; Scott C Silvestry; Gregory Ewald; Joseph G Rogers; Carmelo A Milano; J Eduardo Rame; Michael A Acker; Eugene H Blackstone; John Ehrlinger; Lucy Thuita; Maria M Mountis; Edward G Soltesz; Bruce W Lytle; Nicholas G Smedira Journal: N Engl J Med Date: 2013-11-27 Impact factor: 91.245
Authors: Alice Sweedo; Lisa M Wise; Yana Roka-Moiia; Fernando Teran Arce; S Scott Saavedra; Jawaad Sheriff; Danny Bluestein; Marvin J Slepian; John G Purdy Journal: Cell Mol Bioeng Date: 2021-08-25 Impact factor: 3.337
Authors: Yaron D Barac; Charles M Wojnarski; Parichart Junpaparp; Oliver K Jawitz; Han Billard; Mani A Daneshmand; Richa Agrawal; Adam Devore; Chetan B Patel; Jacob N Schroder; Carmelo A Milano Journal: J Thorac Cardiovasc Surg Date: 2019-10-16 Impact factor: 5.209